CompletedPhase 2NCT03981523

New Therapies and Biomarkers for Chagas Infection

Studying American trypanosomiasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Texas, El Paso
Principal Investigator
Igor C Almeida, D.Sc.
The University of Texas at El Paso (UTEP)
Intervention
Benznidazole(drug)
Enrollment
450 enrolled
Eligibility
18-50 years · All sexes
Timeline
2019 – 2024

Study locations (3)

Collaborators

Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES) · Barcelona Institute for Global Health · Institute of Parasitology and Biomedicine Lopez Neyra · U.S. Food and Drug Administration (FDA) · Drugs for Neglected Diseases · Mundo Sano Foundation · National Institute of Allergy and Infectious Diseases (NIAID)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03981523 on ClinicalTrials.gov

Other trials for American trypanosomiasis

Additional recruiting or active studies for the same condition.

See all trials for American trypanosomiasis →

← Back to all trials